Skip to main content
TEM logo

Tempus AI, Inc. (TEM) Stock: Price, Forecast & Analyst Target

Tempus AI, Inc. (TEM) — MoonshotScore 33/100 (Weak band), calculated Nov 18, 2026. Price $63.62 (+0.30%), as of the Nov 18, 2026 trading session; market cap $11.6B. Expected results Feb 23, 2027.

Educational signal · not a buy or sell recommendation · How to read this

Market value / cash and short-term investments: 18.20× (cash as of Sep 30, 2026) · expected results Feb 23, 2027

$63.62 +$0.19 (+0.30%) Market Cap $11.6B

Tempus AI, Inc. · TEM · NASDAQ · Healthcare · Medical - Healthcare Information Services

Research dated 2026-09-13: Tempus AI sells molecular diagnostics and connects the resulting clinical and molecular information to software, research tools, trial matching, and data licensing for clinicians and life-sciences companies. Its prospects depend on whether that linked system can keep expanding revenue while moving from persistent operating losses and uneven cash use toward durable self-funding.

Price as of Nov 18, 2026

Key Statistics

33 of 100

MoonshotScore v2 · Tempus AI (TEM)

Weak
Business Quality Solid (61)
Financial Safety Fragile (5)
Valuation Full (45)
Growth Durability Growing (60)
Momentum Surging (87)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

A fragile balance sheet and a full valuation; the market is already moving on it. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Solid; Financial Safety: Fragile; Valuation: Full; Growth Durability: Growing; Momentum: Surging.

  • EPS beat 7 of the last 8 reports
  • Altman Z 2.86 · Piotroski F 2
  • ROE -40.9% · ROA -7.7% · current ratio 2.61 · earnings yield -1.6% · free-cash-flow yield -1.3%

Holding back: balance-sheet strain

Helping: positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for TEM (57 recorded, newest six shown)
RecordedScoreBand
34Weak
34Weak
34Weak
34Weak
33Weak
33Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$63.62
Change on the day+0.30%
52-week range$40.77–$104.32
Market capitalisation$11.6B—
Price / earnings (trailing)-143.61
Shares traded on the day5.35M
Beta (volatility vs the S&P 500)3.61

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 18, 2026: low $43, high $90, latest $64. 4 reported quarters marked, 4 above and 0 below the recorded estimate. $90 $43 high $90 Feb 24, 2026 · Earnings results · reported above the recorded estimate · close $531May 5, 2026 · Earnings results · reported above the recorded estimate · close $502Jul 30, 2026 · Earnings results · reported above the recorded estimate · close $443Nov 2, 2026 · Earnings results · reported above the recorded estimate · close $724 Oct 17, 2025 Nov 18, 2026 · $64 $88Oct 17, 2025$90Oct 31, 2025$68Nov 14, 2025$78Nov 28, 2025$71Dec 12, 2025$63Dec 26, 2025$66Jan 9, 2026$65Jan 23, 2026$55Feb 6, 2026$58Feb 20, 2026$52Mar 6, 2026$47Mar 20, 2026$47Apr 2, 2026$56Apr 17, 2026$55May 1, 2026$44May 15, 2026$50May 29, 2026$48Jun 12, 2026$56Jun 26, 2026$58Jul 10, 2026$43Jul 24, 2026$52Aug 7, 2026$73Aug 21, 2026$65Sep 4, 2026$78Sep 18, 2026$77Oct 2, 2026$65Oct 16, 2026$72Oct 30, 2026$72Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate
How to read these dates

Estimated dates can change.

What to watch next

Other perspectives

Council score for Tempus AI (TEM): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Moderate
Financial Safety Negative
Valuation Neutral
Growth Durability Moderate
Momentum Strong

Legends Council

4 lenses, 4 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Strong
Debt/Equity Negative
ROE Negative
Gross Margin Strong

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

One of these lenses reads this company more favourably than the MoonshotScore does: Dalio-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Tempus AI (TEM), and what does it report?

Short answer · as of

A healthcare-information label can suggest a software vendor, but Tempus is also a laboratory diagnostics business.

Its assays generate molecular results, while Hub, Lens, Insights, Trials, Next, and Algos extend those results into clinical workflow, research, data licensing, trial matching, and algorithm-based diagnostics.

Reported revenue therefore blends testing activity with software- and data-oriented offerings. Diagnostics supplies most of the disclosed revenue, making test demand central even though the broader platform reaches physicians, researchers, and life-sciences collaborators.

2 · Latest results

What do the latest results show for Tempus AI (TEM)?

Revenue rebounded in the latest period and gross profit rose with it. The operating loss narrowed, while the reported net result crossed into profit after a substantial loss in the preceding period.

That profit does not yet establish a durable earnings model. Research and development together with selling and administrative expense remained above gross profit, operating cash flow was still negative, and recent cash generation has moved sharply between inflow and outflow even as reported revenue has generally cleared expectations.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Latest quarter · revenue
$411.54M Sep 30, 2026
Latest quarter · R&D
$91.71M Sep 30, 2026
Latest quarter · SG&A
$231.86M Sep 30, 2026
Latest quarter · FMP standardized operating result
−$56.86M Sep 30, 2026
Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026$411.54M$91.71M$231.86M−$56.86M
Jun 30, 2026$382.49M$96.57M$225.84M−$75.91M
Mar 31, 2026$348.12M$94.16M$212.59M−$84.71M
Dec 31, 2025$367.21M$90.62M$192.20M−$61.41M
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$411.54M Nov 2, 2026
Latest report · revenue estimate
$409.39M Nov 2, 2026
Latest report · revenue vs estimate
Above estimate Nov 2, 2026
Latest report · EPS vs estimate
Above estimate Nov 2, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Nov 2, 2026$411.54M$409.39M$0.0700−$0.0937
Jul 30, 2026$382.49M$379.69M−$0.0400−$0.1428
May 5, 2026$348.12M$345.44M−$0.1300−$0.2100
Feb 24, 2026$367.21M$362.55M−$0.0400−$0.0438
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$334M-$80M-$0.46 (diluted)
Q4 FY2025$367M-$54M-$0.30 (diluted)
Q1 FY2026$348M-$126M-$0.71 (diluted)
Q2 FY2026$382M$6M$0.03 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Tempus AI (TEM)?

Short answer

Cash and short-term investments were $637.35M at the Sep 30, 2026 balance-sheet date. Operating cash flow was $9.22M for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.

Cash and investments provide meaningful room against the recent pace of operating and capital spending, and liquidity increased from the preceding period. The runway estimate indicates that current resources can absorb continued burn for a substantial interval if the recent usage rate holds.

Debt nevertheless exceeds cash and investments, so Tempus does not have a net-cash balance sheet. The main financial risk is that diagnostics, licensing, and research demand slow while research and commercial spending remain elevated; that combination would prolong operating losses and consume liquidity before the platform becomes self-funding.

Data-derived red flags

  • Negative return on equity (-40.9%) — the business is not currently generating profit on shareholder capital.
  • Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.

How much cash does the business generate or use?

Quarterly operating cash flow shows cash generated or used by operations.

Latest quarter · operating cash flow
$9.22M Sep 30, 2026
Previous quarter · operating cash flow
−$7.52M Jun 30, 2026
Period endOperating cash flowCapital expenditure (reported)
Sep 30, 2026$9.22M−$14.76M
Jun 30, 2026−$7.52M−$11.09M
Mar 31, 2026−$73.28M−$10.07M
Dec 31, 2025−$36.79M−$6.34M
How to read these figures

Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.

4 · What to check next?

What should you watch next at Tempus AI (TEM)?

Short answer · as of

The next earnings report is expected on Feb 23, 2027.

Revenue, operating loss, and operating cash flow now need to improve together. Continued sales growth would be less persuasive if research and commercial spending keep gross profit from reaching the operating line or if cash use widens again.

Watch whether the upcoming result extends the pattern of revenue exceeding expectations, whether operating cash flow stays near balance, and whether liquidity improves without a matching rise in debt. Longer-range estimates assume continued revenue expansion and eventual positive earnings, making operating leverage the practical test of that path.

5 · Peer comparison

How does Tempus AI compare with its peers?

Short answer

Tempus AI's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Compared with a laboratory business focused only on processing tests, Tempus carries diagnostic results into physician workflow, research applications, trial matching, and licensed data. Compared with healthcare software that sits apart from testing, it also produces molecular and pathology information through its own diagnostic capabilities.

The distinctive mechanism is the feedback loop between assays, multimodal clinical information, and applications built for clinicians and life-sciences customers. That breadth creates more routes to revenue, but diagnostics remains the largest disclosed component, so the software and data narrative cannot be evaluated separately from laboratory execution.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Hinge Health, Inc. (HNGE) Same industry, near in market value$114.53 Nov 18, 2026$9.31B97 5-pillar Nov 18, 2026
Neurocrine Biosciences, Inc. (NBIX) Named competitor$162.86 Nov 18, 2026$16.5B95 5-pillar Nov 18, 2026
Doximity, Inc. (DOCS) Same industry, near in market value$30.67 Nov 18, 2026$5.47B95 5-pillar Nov 18, 2026
Progyny, Inc. (PGNY) Same industry, near in market value$36.16 Nov 18, 2026$2.66B95 5-pillar Nov 18, 2026
Medpace Holdings, Inc. (MEDP) Named competitor$646.87 Nov 18, 2026$18.1B92 5-pillar Nov 18, 2026
Veeva Systems Inc. (VEEV) Same industry, near in market value$262.92 Nov 19, 2026$42.6B92 5-pillar Nov 18, 2026
Centene Corporation (CNC) Named competitor$65.62 Nov 19, 2026$32.5B91 5-pillar Nov 18, 2026
HealthEquity, Inc. (HQY) Same industry, near in market value$97.31 Nov 18, 2026$8.05B90 5-pillar Nov 18, 2026
BrightSpring Health Services, Inc. (BTSG) Same industry, near in market value$68.34 Nov 18, 2026$13.6B87 5-pillar Nov 18, 2026
Smith & Nephew plc (SNN) Named competitor$30.32 Nov 18, 2026$12.7B84 5-pillar Nov 18, 2026
Privia Health Group, Inc. (PRVA) Same industry, near in market value$24.60 Nov 18, 2026$3.14B79 5-pillar Nov 18, 2026
GE HealthCare Technologies Inc. (GEHC) Same industry, near in market value$83.66 Nov 18, 2026$37.8B74 5-pillar Nov 18, 2026
Tempus AI (TEM) — this page$63.62$11.6B33

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$50.00 – $100.00
Consensus target
$77.83
Median target
$78.00

Consensus record · Captured .

Measured against a quoted price of $63.62 (as of Nov 18, 2026).

Insider activity

Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Nov 2, 2026

Transactions
153
Identified insiders
9
Purchases
0
Sales
148
Other transactions
5

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Institutional ownership
62.6% Period end Sep 30, 2026
Previous quarter · ownership
62.3% Prior to period end Sep 30, 2026
Reporting holders
624 Period end Sep 30, 2026
Previous quarter · holders
543 Prior to period end Sep 30, 2026
Holders in provider snapshotShares
Blackrock, INC.9,624,840
Ark Investment Management LLC9,357,545
Baillie Gifford & Co6,911,932
Softbank Group Corp.5,405,406
Jpmorgan Chase & Co5,326,447

Tracked investors

Which of the 16 named investors we follow held TEM in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
ARK InvestCathie WoodQ3 20264.41%$766.38MTrimmed −6.6% shares

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Tempus AI (TEM)?

Read these with our analysis →

TEM Healthcare Stock FAQ

The last 2 questions are answered from this page's own dated data, not from the research.

How do Tempus xT and xR connect with Hub?

The assays generate broad molecular information, while Hub gives healthcare providers an end-to-end clinical application for ordering and using diagnostic tests. Together they link laboratory work with the clinician’s desktop rather than treating the test as a standalone product.

What do Tempus Lens and Insights sell to life-sciences customers?

Lens supports life-sciences research, while Insights licenses linked, de-identified clinical, molecular, and imaging information. These offerings commercialize the company’s data and analytical capabilities beyond patient testing.

Why does Diagnostics shape Tempus AI’s reported business?

Diagnostics contributes most of the disclosed segment revenue, so assay demand remains the clearest reported measure of commercial scale. The applications and data businesses broaden the model, but they do not make Tempus a pure software company.

What does the recent Tempus insider selling pattern establish?

The disclosed activity shows sales by several insiders and no purchases during the measured window. Transaction records establish what occurred, but they do not establish why an insider sold.

What is the TEM stock price today?

The last price recorded for Tempus AI, Inc. (TEM), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the TEM price target?

The analyst consensus price target for Tempus AI, Inc. (TEM), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 80 figures on this page — 1 from SEC filings and earnings calls, 71 from Financial Modeling Prep (FMP), 4 with no recorded source, 3 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Legal name; Business description; Sector / industry (provider taxonomy); Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions)
  • 1. What is Tempus AI (TEM), and what does it report?: Business description; Sector / industry (provider taxonomy); Revenue by segment; Annual revenue and net result (USD millions)
  • 2. What do the latest results show for Tempus AI (TEM)?: Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Reported versus estimated, last 8 quarters; Trailing twelve-month ratio set; Most recent periodic reports
  • 3. What are the financial strengths and risks for Tempus AI (TEM)?: Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash runway cross-check (ours); Cash against market value; Operating cash flow by quarter (USD millions); Quarterly income statement (USD thousands); Trailing twelve-month ratio set; Distress and quality screens; Business description
  • 4. What should you watch next at Tempus AI (TEM)?: Next earnings report; Analyst revenue and earnings estimates (average); Reported versus estimated, last 8 quarters; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash and short-term investments over time (USD millions)
  • 5. How does Tempus AI compare with its peers?: Business description; Revenue by segment; Annual revenue and net result (USD millions)
  • FAQ: How do Tempus xT and xR connect with Hub?: Business description
  • FAQ: What do Tempus Lens and Insights sell to life-sciences customers?: Business description
  • FAQ: Why does Diagnostics shape Tempus AI’s reported business?: Revenue by segment; Annual revenue and net result (USD millions); Business description
  • FAQ: What does the recent Tempus insider selling pattern establish?: Insider transactions, last 180 days; What the sources do not tell us
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold TEM

Funds in our ETF coverage that list TEM among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
ARK Innovation ETF (ARKK)6.16%